Email updates

Keep up to date with the latest news and content from BMC Cancer and BioMed Central.

Open Access Research article

Paclitaxel and concomitant radiotherapy in high-risk endometrial cancer patients: preliminary findings

Giorgia Mangili1*, Patrizia De Marzi1, Saverio Beatrice2, Emanuela Rabaiotti1, Riccardo Viganò1, Luigi Frigerio3, Cinzia Gentile1 and Ferruccio Fazio4

Author Affiliations

1 Gynecology Department, San Raffaele Hospital, Milan, Italy

2 Radiotherapy Department, San Raffaele Hospital, Milan, Italy

3 Gynecology Department Ospedali Riuniti, Bergamo, Italy

4 CNR IBSM, University of Milano-Bicocca, Nuclear Medicine Department, San Raffaele Hospital, Milan, Italy

For all author emails, please log on.

BMC Cancer 2006, 6:198  doi:10.1186/1471-2407-6-198

Published: 25 July 2006

Abstract

Background

There is still much debate about the best adjuvant therapy after surgery for endometrial cancer (EC) and there are no current guidelines. Radiotherapy (RT) alone does not seem to improve overall survival. We investigated whether concomitant Paclitaxel (P) and RT gave better clinical results.

Methods

Twenty-three patients with high-risk EC (stage IIB, IIIA, IIIC or IC G3 without lymphadenectomy or with aneuploid tumor) underwent primary surgery and were then referred for adjuvant therapy. P was given at a dose of 60 mg/m2 once weekly for five weeks during RT, which consisted of a total radiation dose of 50.4 Gy. Three further weekly cycles of P at a dose of 80 mg/m2 were given at the end of RT. Overall survival and disease-free survival were calculated from the time of surgery. Patterns of failure were recorded by the sites of failure.

Results

A total of 157 cycles of P were administered both during radiotherapy and consolidation chemotherapy.

Relapses occurred in five patients (21.7%). Median time to recurrence was 18.6 months (range 3–28). Survival rate for all the patients was 78.2%. Overall survival for the patients who completed chemo-radiation was of 81%. In this group median time to recurrence was 19.2 months (range 3–28). All recurrences were outside the radiation field. Mortality rate was 14.2%.

Conclusion

This small series demonstrates pelvic radiotherapy in combination with weakly P followed by three consolidation chemotherapy cycles as an effective combined approach in high risk endometrial carcinoma patients.